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Abstract: Background: Molecular biomarkers have the potential to predict response to the treatment
of rectal cancer. In this study, we aimed to evaluate the prognostic and clinicopathological implication
of RAD50 (DNA repair protein RAD50 homolog) expression in rectal cancer. Methods: A total of
266 rectal cancer patients who underwent surgery and received chemo- and radiotherapy between
2000 and 2011 were involved in the study. Postoperative RAD50 expression was determined by
immunohistochemistry in surgical samples (n = 266). Results: Using Kaplan–Meier survival analysis,
we found that low RAD50 expression in postoperative samples was associated with worse disease free
survival (p = 0.001) and overall survival (p < 0.001) in early stage/low-grade tumors. In a comparison
of patients with low vs. high RAD50 expression, we found that low levels of postoperative RAD50
expression in rectal cancer tissues were significantly associated with perineural invasion (p = 0.002).
Conclusion: Expression of RAD50 in rectal cancer may serve as a prognostic biomarker for long-term
survival of patients with perineural invasion-positive tumors and for potential use in early stage and
low-grade rectal cancer assessment.
Keywords: RAD50; DNA damage response; rectal cancer; prognosis; biomarkers
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1. Introduction
As the second most common cause of cancer-related death [1], colorectal cancer (CRC) represents
a major worldwide health burden. CRC is the third most commonly diagnosed cancer in men and
the second in women, with the highest prevalence in Australasia, the Asia-Pacific, Western Europe,
and North America [1]. In the United States in 2016, there were approximately 134,490 new cases of
CRC (representing 8% of all new cancer cases), and 49,190 estimated deaths [2].
Surgical resection combined with chemotherapy (with or without radiotherapy) is the standard
CRC treatment [3–5]. Due to local anatomy, surgery alone is usually insufficient to manage patients
with rectal cancer; limited operative access, the distance between the tumor border and the mesorectal
fascia, and vicinity to the pelvic organs all contribute to recurrence [6]. Additionally, rectal cancer
patients consistently have poorer survival outcomes than those with colon cancer [7]. When compared
to surgery alone, the use of preoperative (neoadjuvant) radiotherapy significantly reduces the risk of
recurrence and improves overall survival (OS) and cancer-specific survival [8–10].
The DNA damage response (DDR) signaling pathways identify and repair DNA damage [11].
Cells with defective DDR are unable to repair radiation-induced DNA double-strand breaks and
therefore have increased sensitivity to radiotherapy. Hence, molecules that are involved in DDR
are excellent candidates for radiosensitivity biomarkers [11]. Importantly, abnormalities in DDR
mechanisms are linked to carcinogenesis in many human cancers, including CRC. In particular,
mismatch repair (MMR) proteins recognize and repair single-nucleotide mismatches in microsatellite
sequences that have escaped DNA polymerase proofreading [12]. Approximately 15% of CRCs
have mutations in MMR proteins, causing error accumulation during DNA replication and
recombination, which result in microsatellite instability (MSI) [12]. The MSI tumor phenotype is
of potential clinical significance as a predictor of therapeutic efficacy and prognosis; for example,
compared with microsatellite-stable (MSS) tumors with a functional MMR system, MSI tumors
have better prognosis [13] but exhibit variable treatment outcomes in response to DNA-targeting
chemotherapeutic agents [14].
The MRN complex comprising of DNA repair proteins MRE11, RAD50 and NBS1 (MRE11/RAD50/
NBS1) detects and repairs double-strand breaks, and is therefore critical for maintaining genomic
integrity and suppressing tumor progression [15–17]. Several studies have shown that MRE11
and/or RAD50 mutations often occur in MSI CRC [14,18]. Furthermore, RAD50 is more commonly
overexpressed in MSS tumors, while it is more often mutated in MSI tumors [19]. Similarly, MRE11
is a valuable prognostic marker in CRC [20], and its deficiency is associated with improved OS and
disease-free survival (DFS) in patients with stage III colon cancer, irrespective of treatment [21].
Together with the radiosensitivity index [11,22], MRE11 has been the most studied MRN
complex component, and its prognostic value has been assessed in different cancers [15,23], including
CRC [18,20,24,25]. However, to date, there is no data available on RAD50 as a specific biomarker
in rectal cancer. A recent study evaluated all three MRN proteins together with clinicopathological
factors in low-grade epithelial ovarian cancer, and found that RAD50 loss occurred in 10% of cases
and was associated with MMR deficiency [26]. Based on the key role played by RAD50 in DNA
damage repair [11], we hypothesized that different expression levels of this protein might impact upon
treatment outcomes.
In this study, we evaluated the role of RAD50 as a potential prognostic marker in patients with
incident cases of rectal cancer treated with surgery and radiotherapy. We correlated postoperative
RAD50 tumor expression with patient DFS and OS. Additionally, we assessed the influence of RAD50
expression on other relevant tumor clinico-histopathological variables such as perineural invasion.
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2. Results
2.1. Study Population
A total of 266 patients were included in this study; 176 (66.2%) were male, 90 (33.8%) were female,
and the median age was 72 years (range: 35–100 years) (Table 1). Of 266 patients, 77 (31.3%) were
treated with radiotherapy, 55 of which (71.4%) received preoperative therapy. Patients were followed
for a median period of 3.16 years (range: 0−12.6 years), and the median time to death was 2.5 years
after surgery (range: 0−11.1 years).
Table 1. Patient characteristics.




























2.2. Association between RAD50 Expression and Clinicopathological Features and Prognosis
The association between postoperative RAD50 expression and clinicopathological characteristics
is presented in Table 2. Low RAD50 expression levels in the tumor periphery (TP) were significantly
associated with adjuvant therapy treatment (p = 0.04). There were no significant differences in age,
sex, histological tumor stage, lymph node involvement, metastasis, vascular invasion, or perineural
invasion between patients with low and high RAD50 expression. Kaplan–Meier survival analysis
demonstrated that low RAD50 expression in the tumor center (TC) was significantly associated with
worse DFS (p = 0.016; Figure 1A), whereas the association of RAD50 expression and OS was of
borderline significance (p = 0.056; Figure 1B). No significant difference in survival was seen between
patients with high or low RAD50 expression in the TP (DFS, p = 0.295; OS, p = 0.695) (Figure 1C,D).
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Table 2. Associations between RAD50 protein expression in the tumor center and tumor periphery and
clinicohistopathological data.
Variables Subgroups
Tumor Center Tumor Periphery
Low (%) High (%) p Value Low (%) High (%) p Value
Sex
Male 26.3 73.7 0.98 29.6 70.4 0.42
Female 26.1 73.9 34.4 65.6
Age ≤72 28.8 71.2 0.39 30.6 69.4 0.82
>72 24.1 75.9 31.9 68.1
Tumor stage T1–2 23.5 76.5 0.65 32.1 67.9 0.68
T3–4 26.2 73.8 29.6 70.4
Node stage Negative 26.5 73.5 0.67 31.1 68.9 0.95
Positive 24.1 75.9 30.8 69.2
Metastasis stage M0 25.5 74.5 0.72 31.5 68.5 0.09
M1 29.4 70.6 11.8 88.2
Histological Grade 1–2 26.1 73.9 0.88 31.3 68.7 0.98
3 27.8 72.2 31.6 68.4
Vascular invasion
Absent 26.3 73.7 0.74 31.9 68.1 0.50
Present 24.2 75.8 27.4 72.6
Perineural invasion
Absent 24.7 75.3 0.40 32.2 67.8 0.28
Present 31.1 68.9 23.8 76.2
Adjuvant therapy No 25.2 74.8 0.83 24.8 75.2 0.04
Yes 26.6 73.4 38.8 61.2
Neoadjuvant therapy No 23.8 76.2 0.14 27.1 72.9 0.16
Yes 34.1 65.9 37.3 62.7
Tumor regression grade 0–1 50 50 0.14 50 50 0.22
2–3 28.3 71.7 32.8 67.2
MSH6
Negative 50.0 50.00 0.43 0 100 0.35
Positive 25.5 74.5 30.8 69.2
PMS2
Negative 55.6 44.4 0.04 44.4 55.6 0.36
Positive 25.5 74.5 30.1 69.9
RAD50: DNA repair protein RAD50 homolog; MSH6: MutS protein homolog 6; PMS2: PMS1 homolog 2.
To explore the association between RAD50 scores and clinical prognosis, the samples were
further categorized into a high expression group (score range: 6–12), a medium-low expression group
(score range: 4–<6), and a very low expression group (score range: 0–<4). Kaplan–Meier survival
analysis revealed that very low RAD50 expression in the TC was significantly associated with worse
DFS (p = 0.031) and decreased OS (p = 0.044), indicating that the loss of RAD50 expression would
possibly increase tumor aggressiveness (Figure S1A,B). No significant change was found between
patients with high, medium-low, or/and very low RAD50 expression in the TP (DFS, p = 0.111; OS,
p = 0.638; Figure S1C,D).
We next investigated the status of the MMR pathway in patient samples by evaluating the
association of MMR proteins with RAD50 expression. All cases were positive for MLH1 (MutL
protein homolog 1) and MSH2 (MutS protein homolog 2) expression; therefore, none of the cases were
classified as MSI-high (MMR-negative). Expression of MSH6 (MutS protein homolog 6) and PMS2
(PMS1 homolog 2) were negative in 2/253 (0.8%) and 9/253 (3.6%) cases, respectively. Additionally,
no significant associations of RAD50 and MSH6 expression in either TC or TP samples were found.
Finally, low postoperative RAD50 expression was significantly associated with PMS2 expression in the
TC (p = 0.04), but not in the TP (p = 0.36) (Table 2).
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Figure 1. Association between postoperative RAD50 (DNA repair protein RAD50 homolog) 
expression in the TC (tumor core) and TP (tumor periphery) and survival. (A–D) Kaplan–Meier 
survival analysis illustrating DFS (disease free survival) (A,C) and OS (overall survival) (B,D) of 
patients with RAD50 expression in the TC (A,B) and TP (C,D). Blue lines represent patients with 
low RAD50 expression and green lines represent patients with high RAD50 expression. 
We found that low expression of RAD50 in the TC (HR (hazard ratio) = 0.552, 95% CI 0.339–
0.899, p = 0.017; univariate Cox regression) was significantly associated with reduced DFS (Table 3). 
Representative immunohistochemical staining of high and low RAD50 expression in rectal cancer 
tissues are shown in Figure 2A,B. Additionally, using multivariate Cox analysis, we found that 
RAD50 expression (HR = 0.567, 95% CI 0.345–0.931, p = 0.025) and perineural invasion (HR = 2.364, 
95% CI 1.343–4.162, p = 0.003) remained significantly associated with DFS (Table 3). However, in 
multivariate Cox analysis with OS, perineural invasion (HR = 1.701, 95% CI 1.036–2.792, p = 0.036) 
remained significantly associated with OS, but not with tumor RAD50 expression (HR = 0.712, 95% 
CI 0.462–1.095, p = 0.122) (Table S1). Finally, using Kaplan–Meier analysis of DFS to compare 
RAD50 low and high expression groups with tumors classified by perineural invasion status, we 
found that low levels of RAD50 expression in rectal cancer tissues were significantly associated 
with perineural invasion (Figure 2C,D), indicating that low RAD50 in the context of PNI (perineural 
invasion) is a marker of poor prognosis.  
Table 3. Cox regression analyses of postoperative RAD50 with disease-free survival. 
Variables 
Univariate Multivariate
HR  95% CI p-Value HR 95% p-Value  
RAD50 
Low 0.552 0.339–0.899 0.017 0.567 0.345–0.931 0.025 
High 
Figure 1. Association between postoperative RAD50 (DNA repair protein RAD50 homolog) expression
in the TC (tumor core) and TP (tumor periphery) and survival. (A–D) Kaplan–Meier survival analysis
illustrating DFS (disease free survival) (A,C) and OS (overall survival) (B,D) of patients with RAD50
expression in the TC (A,B) TP (C,D). Blue li es repre en patients with low RAD50 expression and
green lines represent patients with high RAD50 expression.
We found that low expression of RAD50 in the TC (HR (hazard ratio) = 0.552, 95% CI 0.339–0.899,
p = 0.017; univariate Cox regression) was significantly associated with reduced DFS (Table 3).
Representativ immunohistochemical staining of high and low RAD50 express on in rectal cancer tissues
are shown in Figure 2A,B. Additionally, using mult variate C x nalys s, we found that RAD50 expression
(HR = 0.567, 95% CI 0.345–0.931, p = 0.025) and perineural invasion (HR = 2.364, 95% CI 1.343–4.162,
p = 0.003) remained significantly associated with DFS (Table 3). However, in multivariate Cox analysis
with OS, perineural invasion (HR = 1.701, 95% CI 1.036–2.792, p = 0.036) remained significantly associated
with OS, but not with tumor RAD50 expression (HR = 0.712, 95% CI 0.462–1.095, p = 0.122) (Table S1).
Finally, using Kaplan–Meier analysis of DFS to compare RAD50 low and high expression groups with
tumors cl ssified by perineural invasion tatus, we found that low levels of RAD50 expression in rectal
cancer tissues were significantly associated with perineural invasion (Figure 2C,D), indicating that low
RAD50 in the context of PNI (perineural invasion) is a marker of poor prognosis.
Table 3. Cox regression analyses of postoperative RAD50 with disease-free survival.
Variables
Univariate Multivariate
HR 95% CI p-Value HR 95% p-Value
RAD50
Low 0.552 0.339–0.899 0.017 0.567 0.345–0.931 0.025
High




HR 95% CI p-Value HR 95% p-Value
Age
≤72 1.279 0.785–2.086 0.323
>72
Sex
Male 1.074 0.657–1.754 0.776
Female
Tumor stage
T1–2 1.643 0.983–2.747 0.058
T3–4
Node stage
Negative 1.198 0.709–1.827 0.593
Positive
Histological Grade
1–2 1.646 0.712–3.804 0.244
3
Vascular invasion
Absent 1.888 0.650–0.2.171 0.575
Present
Perineural invasion
Absent 2.534 0.373–1.134 0.001 2.364 1.343–4.162 0.003
Present
Adjuvant therapy
No 0.65 0.373–1.134 0.129
Yes
Neoadjuvant therapy
No 1.147 0.672–0.957 0.616
Yes
T1–2, G1–2, † RAD50 0.218 0.084–0.570 0.002
T3–4, G3, † RAD50 0.401 0.065–2.471 0.324
HR, hazard ratio; CI, confidence interval; TC, tumor center, † denotes interaction.
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Figure 2. Correlation between RAD50 expression and perineural invasion (PNI) and survival in 
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Kaplan–Meier survival analysis of DFS in low RAD50 expression (C) and high RAD50 expression 
(D) groups with (green line) or without (blue line) perineural invasion; (E,F) Kaplan–Meier survival 
analysis illustrating the relationship of RAD50 expression with DFS (E) and OS (F) in low-grade 
(G1–2) with early tumor stage (T1–2) subgroup. The analyses were divided into four subgroups 
including the low-grade with early stage tumors (G1–2, T1–2, n = 64), high-grade with early stage 
tumors (G3, T1–2, n = 4), low-grade with late stage tumors (G1–2, T3–4, n = 113), and high-grade 
with late stage tumors (G3, T3–4, n = 8).  
2.3. RAD50 Expression as a Putative Prognostic Factor for Early Stage Rectal Cancer 
The DFS of rectal cancer patients with low RAD50 expression was worse than the DFS of 
patients with high RAD50 expression. When patients were grouped into early tumor stage (T1–2) 
and low-grade (G1–2) subgroups, low expression of RAD50 was associated with decreased DFS (p = 
0.001) (Figure 2E), indicating that RAD50 may be a useful prognostic biomarker for early tumor 
stage and low-grade subgroups. Similarly, low RAD50 expression in early tumor stage and low-
grade tumor subgroups was significantly associated with worse OS (p < 0.001) (Figure 2F). Additional 
Cox regression analyses confirmed that expression of RAD50 in early tumor stage and low-grade 
subgroups significantly correlated with DFS (HR = 0.218, 95% CI 0.084–0.570, p = 0.002) (Table 3). 
3. Discussion 
Colon and rectal cancers are often considered as a single entity and are treated with similar 
approaches. However, rectal cancers, particularly localized rectal cancers, may benefit from a 
different approach. In this study, we evaluated RAD50 expression by immunohistochemistry in 266 
rectal cancer samples, taking into account several clinicopathological characteristics, as well as the 
Figure 2. Correlation between RAD50 expression and perineural invasion (PNI) and survival in early
stage rectal cancers. (A,B) Representative immunohistochemical staining of RAD50 in rectal cancer
samples (high versus low expression), images were taken at 10× magnification; (C,D) Kaplan–Meier
survival analysis of DFS in low RAD50 expression (C) and high RAD50 expression (D) groups with
(green line) or without (blue line) perineural invasion; (E,F) Kaplan–Meier survival analysis illustrating
the relationship of RAD50 expression with DFS (E) and OS (F) in low-grade (G1–2) with early tumor
stage (T1–2) subgroup. The analyses were divided into four subgroups including the low-grade with
early stage tumors (G1–2, T1–2, n = 64), high-grade with early stage tumors (G3, T1–2, n = 4), low-grade
with late stage tumors (G1–2, T3–4, n = 113), and high-grade with late stage tumors (G3, T3–4, n = 8).
2.3. RAD50 Expression as a Putative Prognostic Factor for Early Stage Rectal Cancer
The DFS of rectal cancer patients with low RAD50 expression was worse than the DFS of patients
with high RAD50 expression. When patients were grouped into early tumor stage (T1–2) and low-grade
(G1–2) subgroups, low expression of RAD50 was associated with decreased DFS (p = 0.001) (Figure 2E),
indicating that RAD50 may be a useful prognostic biomarker for early tumor stage and low-grade
subgroups. Similarly, low RAD50 expression in early tumor stage and low-grade tumor subgroups
was significantly associated with worse OS (p < 0.001) (Figure 2F). Additional Cox regression analyses
confirmed that expression of RAD50 in early tumor stage and low-grade subgroups significantly
correlated with DFS (HR = 0.218, 95% CI 0.084–0.570, p = 0.002) (Table 3).
3. Discussion
Colon and rectal cancers are often considered as a single entity and are treated with similar
approaches. However, rectal cancers, particularly localized rectal cancers, may benefit from a different
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approach. In this study, we evaluated RAD50 expression by immunohistochemistry in 266 rectal cancer
samples, taking into account several clinicopathological characteristics, as well as the type of treatment
received. We discovered that low levels of RAD50 expression at early tumor stages and low-grade
tumor subgroups were significantly associated with worse DFS and OS, indicating a relationship
between postoperative tumor expression of RAD50 and prognosis.
Long-term clinical trials [27,28] and several meta-analyses [8,10,29] have confirmed that
neoadjuvant radiotherapy plus surgery reduces the rate of local recurrence and increases the survival
rate of rectal cancer patients, benefits that outweigh the associated side effects. Patients with rectal
cancer can have variable responses to radiotherapy; therefore, the identification of rectal cancer-specific
radiosensitivity and prognostic markers would enable targeted therapeutic decisions, which would
likely improve treatment results and survival rates. For example, it would be useful to identify
biomarkers that discriminate between patients who are likely to benefit from neoadjuvant (preoperative)
radiotherapy and those who would respond better to adjuvant (postoperative) radiotherapy.
Based on this premise, we investigated RAD50 as a prognostic biomarker in rectal cancer.
Together with MRE11 and NBS1, RAD50 is part of the MRN complex, which is heavily involved in
maintenance of genomic integrity and tumor suppression [15]. An intact MRN complex predicts a good
response to treatment in patients with early breast cancer [30], whereas mutations in MRE11, NBS1,
or RAD50 have been linked to increased risk of cancer, including sporadic and familial cancers [17].
We correlated the clinicopathological characteristics and treatment type with long-term (DFS and
OS) radiotherapy responses. Specifically, the results from univariate and multivariate analyses showed
that worse DFS outcomes were associated not only with low RAD50 expression in the TC, but also
with perineural invasion. These data indicate that postoperative RAD50 expression predicts long-term
survival if evaluated with other tumor-related clinicopathological features.
We found that low postoperative RAD50 expression was associated with reduced DFS and OS
in early tumor stage (T1–2) and low-grade (G1–2) patient subgroups, supporting the potential use of
RAD50 as an early prognostic biomarker in rectal cancer. The role of RAD50 has also been evaluated
in CRC. Of interest, Gao et al. [19] demonstrated that RAD50 expression is weak in MSI CRCs and is
not associated with clinicopathological characteristics. Conversely, they observed increased RAD50
expression in early stage primary MSS CRCs. Interestingly, they found that the oncogenic RAD50
frameshift mutation (A)9 occurred in MSI, but not in MSS CRCs, which suggests that RAD50 might
play different roles in these CRC phenotypic subtypes [19].
Importantly, RAD50 was identified as a prognostic biomarker for colorectal mucinous
adenocarcinoma (10–15% of all cases) through an integrated analysis of genetic and epigenetic
features [31]. The authors of this study showed that weak RAD50 expression was associated with poor
prognosis in patients with MSS CRC, and postulated that increased RAD50 expression in MSS CRC
could be a tumor suppressive cellular response to prevent further tumor progression [31]. Based on
these reports, further investigation of the molecular role of RAD50 in MSI and MSS CRCs could help
inform patient response to therapy.
A limitation of the study was that we focused on individual TNM (tumor, node and metastases)
factors rather than overall TNM staging. The current study involved two centers with limited numbers
of patients that could have been influenced by our local experience in rectal cancer management. Thus,
larger, multicenter prospective studies are needed.
4. Materials and Methods
4.1. Patients
The study was approved by the South Western Sydney Local Health District Human Research
Ethics Committee (HREC Reference: HREC/14/LPOOL/186; project number 14/103). Specimens were
collected from 266 patients who underwent surgery and radiotherapy for rectal cancer from 2000–2011.
Patients were treated with either a 25 Gy dose administered in five treatment fractions, or a 50.4 Gy
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dose administered in 28 fractions; both treatment groups received 5-fluorouracil-based chemotherapy.
Surgery consisted of total mesorectal excision, as well as anterior or abdominoperineal resection.
Follow-up included clinic visits, blood tests, colonoscopy, and imaging based on the recommendation
of the treating specialist.
4.2. Response and Outcomes of Interest
Short-term response to radiotherapy was measured by TRG (tumor regression grade) according
to the 7th edition of the American Joint Committee on Cancer manual [32], which describes a scale
of 0–3: 0 represents complete response without any viable malignant cells; 1 is a moderate response
with small groups of malignant cells; 2 is a minimal response with fibrosis outgrowing residual
malignancy; and 3 is a poor response with residual malignancy. Patients categorized with a TRG of
0 and 1 were considered responders, while patients categorized with a TRG of 2 and 3 were considered
non-responders. Variables included age, sex, pathological TNM stage, tumor grade, vascular invasion,
perineural invasion, the level of tumor-infiltrating lymphocytes, and treatment. Outcomes were DFS,
OS, and histologic TRG in the resected bowel. Long-term outcomes were assessed using Kaplan–Meier
curves for DFS and OS. DFS was defined as the time from diagnosis to first recurrence, and OS was
defined as the time from diagnosis to the last follow-up point or death.
4.3. Sample Preparation and Tissue Microarrays
Archival formalin-fixed, paraffin-embedded tissue blocks from pre- and postoperative rectal
cancer tumors were retrieved for each patient, and two cores (1 mm in diameter) were obtained from
each of five different sampling sites: tumor center (TC); tumor periphery at invasive edge (TP); normal
mucosa close/adjacent to the tumor; normal mucosa well away from the tumor; and the involved
lymph nodes. The corresponding hematoxylin and eosin sections were reviewed to localize the most
representative areas of tumor and normal colorectal mucosa in tissue samples. These samples were
then transferred into pre-drilled wells in tissue microarray blocks using the Beecher Manual Tissue
Microarrayer (Beecher Instruments Inc., Sun Prairie, WI, USA), which were mounted on slides for
immunohistochemical analysis.
4.4. Immunohistochemistry
Slide sections taken from the tissue microarrays were deparaffinized in xylene and rehydrated
in a graded ethanol series. RAD50 antigen retrieval was performed with the EnvisionTM FLEX
Target Retrieval Solution, pH 9.0, in a 98 ◦C water bath for 45 min. This was followed by incubation
with EnvisionTM FLEX Peroxidase-Blocking Reagent (Dako, Glostrup, Denmark) for 5 min at room
temperature to block endogenous peroxidases. Slides were then incubated with a monoclonal
anti-RAD50 primary antibody [13B3/2C6] (1:400 dilution, Abcam #ab89; Cambridge, UK) for
60 min at room temperature. Following antigen retrieval, primary antibodies against MSH6 (1:100),
and PMS2 (1:100) (all from Dako, Glostrup, Denmark) were applied for 15 min on board the Dako
Autostainer (Dako, Glostrup, Denmark) in 1 mM EDTA (Ethylenediaminetetraacetic acid) buffer,
pH 8.0. After washing with Tris-buffered saline with Tween-20, slides were incubated for 15 min
with DAKO mouse linker, rinsed, and incubated for 30 min with an anti-mouse secondary antibody.
A mixture of EnvisionTM FLEX DAB + Chromogen DM827 and EnvisionTM FLEX Substrate Buffer
DM823 (Dako, Glostrup, Denmark) was used as a substrate for development. Finally, slides were
counterstained with hematoxylin, washed with cold water, and then dipped 10 times in Scott’s Bluing
solution (Thermo Fisher Scientific, North Ryde, NSW, Australia). Slides were rinsed immediately with
cold water before dehydration and mounting.
Two independent pathologists recorded the intensity and percentage of positive
immunohistochemical staining in each sample. RAD50 expression was scored as the product
of the staining percentage and intensity as previously described [20]. Intensity was graded as follows:
0, negative; 1, weak; 2, moderate; or 3, strong. The percentage of positive cells was graded as follows:
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0 (<5%), 1 (5–25%), 2 (26–50%), 3 (51–75%), or 4 (>75%). These two measures were multiplied to obtain
weighted scores ranging from 0 to 12. All tumor samples were categorized into either a low expression
group (score range: 0–<6) or a high expression group (score range: 6–12).
4.5. Statistical Analysis
Statistical analysis was performed with SPSS for Windows 22.0 (IBM Corporation, Armonk, NY,
USA). Survival analysis was conducted for the entire cohort. In addition, further subgroup analysis
was conducted for early tumor stage and low-grade tumors as covariates. Univariate and multivariate
analyses were performed using Kaplan–Meier curves and Cox’s proportional hazards survival
modeling for RAD50 protein expression from the cancer core and periphery. Covariates were sex, age,
TNM stage, tumor grade, vascular invasion, perineural invasion, chemotherapy and radiotherapy,
TRG, MSH6, and PMS2. Univariate analysis was performed using the Mann–Whitney U test. p < 0.05
was considered statistically significant.
5. Conclusions
The status of RAD50 expression may have treatment implications for rectal cancer, particularly
for predicting long-term survival of patients with perineural invasion and for potential use in early
stage and low-grade rectal cancer assessment. Further investigation of RAD50 in larger populations
and the identification of new biomarkers are likely to provide new and effective prognostic tools for
rectal cancer management.
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